Zacks Research Estimates Amgen’s Q1 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Amgen in a research note issued to investors on Wednesday, December 4th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $4.56 per share for the quarter, down from their prior forecast of $4.57. The consensus estimate for Amgen’s current full-year earnings is $19.51 per share. Zacks Research also issued estimates for Amgen’s Q4 2025 earnings at $5.25 EPS, FY2025 earnings at $20.04 EPS, Q1 2026 earnings at $4.67 EPS, Q2 2026 earnings at $5.13 EPS and FY2026 earnings at $20.66 EPS.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 EPS. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis.

AMGN has been the topic of a number of other research reports. Wolfe Research initiated coverage on Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Royal Bank of Canada cut their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Citigroup lowered their target price on Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Finally, Sanford C. Bernstein began coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $323.05.

Amgen Stock Performance

AMGN opened at $274.33 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market capitalization of $147.46 billion, a price-to-earnings ratio of 35.13, a P/E/G ratio of 3.08 and a beta of 0.55. The business’s 50-day moving average price is $307.58 and its two-hundred day moving average price is $316.10. Amgen has a 1 year low of $257.80 and a 1 year high of $346.85.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.28%. Amgen’s payout ratio is presently 115.24%.

Hedge Funds Weigh In On Amgen

Hedge funds have recently bought and sold shares of the business. State Street Corp grew its position in shares of Amgen by 1.2% during the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company’s stock worth $9,446,236,000 after purchasing an additional 345,537 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 0.9% in the third quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company’s stock valued at $3,893,771,000 after buying an additional 103,851 shares during the period. Charles Schwab Investment Management Inc. grew its position in Amgen by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company’s stock worth $3,393,718,000 after buying an additional 251,876 shares in the last quarter. Janus Henderson Group PLC increased its stake in Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company’s stock worth $1,657,183,000 after acquiring an additional 538,545 shares during the period. Finally, Pathway Financial Advisers LLC raised its holdings in Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after acquiring an additional 4,446,757 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.